Sign Up Today and Learn More About Kriya Therapeutics Stock
Invest in or calculate the value of your shares in Kriya Therapeutics or other pre-IPO companies through EquityZen's platform.
Kriya Therapeutics Stock (KRTH)
Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
About Kriya Therapeutics Stock
Founded
2019
Headquarters
Palo Alto, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Kriya Therapeutics Press Mentions
Stay in the know about the latest news on Kriya Therapeutics
Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
globenewswire • Nov 13, 2024
Shankar Ramaswamy, M.D.’s Post
linkedin • Aug 03, 2024
Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer
globenewswire • Jul 10, 2024
Gene Therapy Co. Taps Experienced Bioscience Legal Chief
law360 • Jun 26, 2024
KRIYA-825 ameliorates retinal degeneration in mice, study shows
bioworld • Jun 26, 2024
Kriya Therapeutics Management
Leadership team at Kriya Therapeutics
President and Chief Medical Officer
Ma'an Muhsin
Co-Founder
Fraser Wright
Join now and verify your accreditation status to gain access to:
- Kriya Therapeutics current valuation
- Kriya Therapeutics stock price
- Available deals in Kriya Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Kriya Therapeutics Stock
How to invest in Kriya Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Kriya Therapeutics through EquityZen funds. These investments are made available by existing Kriya Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Kriya Therapeutics stock?
Shareholders can sell their Kriya Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
